Caspase 9b: A new target for therapy in non-small-cell lung cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 4, 2011, Pages 499-502

  Shultz, Jacqueline C ^a   Chalfant, Charles E ^a,b,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

alternative splicing; caspase 9; erlotinib; hnRNPL; non small cell lung cancer; oncogenesis

Indexed keywords

CASPASE 9; DAUNORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN L; MESSENGER RNA;

ALTERNATIVE RNA SPLICING; CANCER DIAGNOSIS; CANCER THERAPY; DOWN REGULATION; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ALTERNATIVE SPLICING; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 9; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 79955083536     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.23     Document Type: Review

References (31)

1. Walker S. Updates in non-small cell lung cancer. Clin. J. Oncol. Nurs. 12(4), 587-596 (2008).
2. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2(3), e73 (2005).
3. Kampa D, Cheng J, Kapranov P et al. Novel RNAs identified from an in-depth analysis of the transcriptome of human chromosomes 21 and 22. Genome Res. 14(3), 331-342 (2004). (Pubitemid 38380391)
4. Johnson JM, Castle J, Garrett-Engele P et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science (New York, NY) 302(5653), 2141-2144 (2003). (Pubitemid 38017950)
5. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res. 64(21), 7647-7654 (2004). (Pubitemid 39446889)
6. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 14(3), 185-193 (2007). (Pubitemid 46355578)
7. Cheng C, Sharp PA. Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol. Cell Biol. 26(1), 362-370 (2006).
8. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol. Cell 33(5), 591-601 (2009).
9. Valacca C, Bonomi S, Buratti E et al. Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. J. Cell Biol. 191(1), 87-99 (2010).
10. Groeger AM, Esposito V, De Luca A et al. Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers. Histopathology 44(1), 54-63 (2004). (Pubitemid 38174871)
11. Karczmarek-Borowska B, Filip A, Wojcierowski J et al. Estimation of prognostic value of Bcl-xL gene expression in non-small cell lung cancer. Lung Cancer (Amsterdam, The Netherlands) 51(1), 61-69 (2006). (Pubitemid 43088625)
12. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit. Rev. Clin. Lab. Sci. 39(6), 527-579 (2002). (Pubitemid 35425379)
13. Shultz JC, Goehe RW, Wijesinghe DS et al. Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res. 70(22), 9185-9196 (2010).
14. Goehe RW, Shultz JC, Murudkar C et al. hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing. J. Clin. Investig. 120(11), 3923-3939 (2010).
15. Ebert AD, Chen F, He X, Cryns VL, Bohn MC. A tetracycline-regulated adenovirus encoding dominant-negative caspase-9 is regulated in rat brain and protects against neurotoxin-induced cell death in vitro, but not in vivo. Exp. Neurol. 191(Suppl. 1), S80-S94 (2005). (Pubitemid 40075413)
16. Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis 9(6), 691-704 (2004). (Pubitemid 40941198)
17. Kominsky DJ, Bickel RJ, Tyler KL. Reovirus-induced apoptosis requires mitochondrial release of Smac/DIABLO and involves reduction of cellular inhibitor of apoptosis protein levels. J. Virol. 76(22), 11414-11424 (2002). (Pubitemid 35231297)
18. Liang Q, Liou AK, Ding Y et al. 6-Hydroxydopamine induces dopaminergic cell degeneration via a caspase-9-mediated apoptotic pathway that is attenuated by caspase-9dn expression. J. Neurosci. Res. 77(5), 747-761 (2004). (Pubitemid 39194617)
19. Philchenkov A, Zavelevich M, Kroczak TJ, Los M. Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp. Oncol. 26(2), 82-97 (2004).
20. Seol DW, Billiar TR. A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis. J. Biol. Chem. 274(4), 2072-2076 (1999).
21. Soengas MS, Alarcon RM, Yoshida H et al. APAF-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science (New York, NY) 284(5411), 156-159 (1999). (Pubitemid 29282071)
22. Srinivasula SM, Ahmad M, Guo Y et al. Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis. Cancer Res. 59(5), 999-1002 (1999). (Pubitemid 29135957)
23. Stephanou A, Scarabelli TM, Knight RA, Latchman DS. Antiapoptotic activity of the free caspase recruitment domain of procaspase-9: a novel endogenous rescue pathway in cell death. J. Biol. Chem. 277(16), 13693-13699 (2002). (Pubitemid 34967970)
24. Wu GS, Ding Z. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene 21(1), 1-8 (2002). (Pubitemid 34076373)
25. Yacoub A, Mitchell C, Hong Y et al. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol. Ther. 3(8), 739-751 (2004). (Pubitemid 41351078)
26. Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Ann. Rev. Med. 55, 433-457 (2004). (Pubitemid 38316736)
27. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22(16), 3238-3247 (2004). (Pubitemid 41103678)
28. Cappuzzo F, Ciuleanu T, Stelmakh L et al. SATURN: a double-blind, randomized, Phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J. Clin. Oncol. 27, 15s (2009).
29. Tockman MS, Mulshine JL, Piantadosi S et al. Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin. Cancer Res. 3(12 Pt 1), 2237-2246 (1997). (Pubitemid 28133141)
30. Sueoka E, Sueoka N, Iwanaga K et al. Detection of plasma hnRNP B1 mRNA, a new cancer biomarker, in lung cancer patients by quantitative real-time polymerase chain reaction. Lung Cancer (Amsterdam, The Netherlands) 48(1), 77-83 (2005). (Pubitemid 40381002)
31. Boukakis G, Patrinou-Georgoula M, Lekarakou M, Valavanis C, Guialis A. Deregulated expression of hnRNP A/B proteins in human non-small cell lung cancer: parallel assessment of protein and mRNA levels in paired tumour/non-tumour tissues. BMC Cancer 10, 434 (2010).